Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Bulks Up In Obesity With Orexigen Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese pharma signs on as a marketing partner for Orexigen's Contrave ahead of a December advisory committee meeting and a Jan. 31 PDUFA date.

You may also be interested in...



New Paradigm Would Open More Avenues To Obesity Drug Approval

Assessments of obesity drugs should look at their effects in patients grouped by health status and FDA should expand the universe of secondary endpoints available to assess benefits, a group of stakeholders says.

Obesity Drug Approval Needs A New Paradigm, Stakeholder Group Says

Group convened by George Washington University School of Public Health and Health Services recommends a “patient-centered” approach to reviewing obesity drugs that includes assessing the therapies for their risks and benefits for obese individuals who are healthy, have risk factors for co-morbidities or impairments to daily feeling or functioning, or are already sick.

Qsymia Sales Reps Recruited For Experience With Metabolic Products

Vivus will benefit from downsizing at other firms, Chief Commercial Officer Mike Miller says. The company will aggressively seek formulary coverage, expects REMS to soothe payer concerns about appropriate use of the obesity product, he notes.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel